EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Crystallographic and Selectivity Studies on the Approved HIF Prolyl Hydroxylase Inhibitors Desidustat and Enarodustat

Thomas P Corner, Eidarus Salah, Anthony Tumber, Samanpreet Kaur, Yu Nakashima, Mark D Allen, Lara I Schnaubelt, Giorgia Fiorini, Lennart Brewitz iD, Christopher J Schofield iD

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Thomas P Corner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield …. Hauptthemen laut MEDLINE: Prolyl-Hydroxylase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Cancer Research UK, Biotechnology and Biological Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolyl hydroxylase domain‐containing proteins 1–3 (PHD1–3) are 2‐oxoglutarate (2OG)‐dependent oxygenases catalysing C‐4 hydroxylation of prolyl residues in α‐subunits of the heterodimeric transcription factor hypoxia‐inducible factor (HIF), modifications that promote HIF‐α degradation via the ubiquitin‐proteasome pathway. Pharmacological inhibition of the PHDs induces HIF‐α stabilisation, so promoting HIF target gene transcription. PHD inhibitors are used to treat anaemia caused by chronic kidney disease (CKD) due to their ability to stimulate erythropoietin (EPO) production. We report studies on the effects of the approved PHD inhibitors Desidustat and Enarodustat, and the clinical candidate TP0463518, on activities of a representative set of isolated recombinant human 2OG oxygenases. The three molecules manifest selectivity for PHD inhibition over that of the other 2OG oxygenases evaluated. We obtained crystal structures of Desidustat and Enarodustat in complex with the human 2OG oxygenase factor inhibiting hypoxia‐inducible factor‐α (FIH), which, together with modelling studies, inform on the binding modes of Desidustat and Enarodustat to active site Fe(II) in 2OG oxygenases, including PHD1–3. The results will help in the design of selective inhibitors of both the PHDs and other 2OG oxygenases, which are of medicinal interest due to their involvement inter alia in metabolic regulation, epigenetic signalling, DNA‐damage repair, and agrochemical resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prolyl-Hydroxylase InhibitorsHumansCrystallography, X-RayHypoxia-Inducible Factor-Proline DioxygenasesStructure-Activity RelationshipHypoxia-Inducible Factor 1, alpha SubunitPyrazolesModels, MolecularMolecular StructureTriazolesPyridinesN-substituted Glycines

Stichwörter der Autor:innen

2-oxoglutarate/α–ketoglutarate non-heme oxygenasesAnaemiaChronic kidney disease (CKD)DesidustatEnarodustatEpigeneticsHIF prolyl hydroxylase (PHD) inhibitorsHypoxiaHypoxia-inducible factor-alpha (HIF-α)TP0463518

Substanzen

Prolyl-Hydroxylase InhibitorsenarodustatHypoxia-Inducible Factor-Proline DioxygenasesHypoxia-Inducible Factor 1, alpha SubunitPyrazolesTriazolesPyridinesN-substituted Glycines

Autor:innen und Institutionen

  • Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, United Kingdom.
  • Present Address: Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut, 06511, United States of America.
  • Institute of Natural Medicine, University of Toyama, 2630-Sugitani, Toyama, 930-0194, Japan.

ORCID-Profile: Lennart Brewitz, Christopher J Schofield

Förderung

  • Wellcome Trust
  • Cancer Research UK
  • Biotechnology and Biological Sciences Research Council

Zitieren

APA

Corner, T. P., Salah, E., Tumber, A., Kaur, S., Nakashima, Y., Allen, M. D., Schnaubelt, L. I., Fiorini, G., Brewitz, L., & Schofield, C. J. (2024). Crystallographic and Selectivity Studies on the Approved HIF Prolyl Hydroxylase Inhibitors Desidustat and Enarodustat. ChemMedChem. https://doi.org/10.1002/cmdc.202400504

Vancouver

Corner TP, Salah E, Tumber A, Kaur S, Nakashima Y, Allen MD, et al. Crystallographic and Selectivity Studies on the Approved HIF Prolyl Hydroxylase Inhibitors Desidustat and Enarodustat. ChemMedChem. 2024. doi:10.1002/cmdc.202400504

BibTeX
@article{Corner2024,
  author = {Corner, Thomas P and Salah, Eidarus and Tumber, Anthony and Kaur, Samanpreet and Nakashima, Yu and Allen, Mark D and Schnaubelt, Lara I and Fiorini, Giorgia and Brewitz, Lennart and Schofield, Christopher J},
  title = {Crystallographic and Selectivity Studies on the Approved HIF Prolyl Hydroxylase Inhibitors Desidustat and Enarodustat},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400504}
}
Kostenlos starten →